Federal Register / Vol. 88, No. 232 / Tuesday, December 5, 2023 / Notices 84335 

Appropriations Act, 2021 (Pub. L. 116– 

260). 

Mary B. Jones, 

ACF/OPRE Certifying Officer. 

[FR Doc. 2023–26658 Filed 12–4–23; 8:45 am] 

BILLING CODE 4184–37–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Community Living 

Agency Information Collection 

Activities; Proposed Collection; 

Comment Request; ACL Program 

Performance Report Generic 

Information Collection, OMB 0985– 

NEW 

SUMMARY: The Administration for 

Community Living (ACL) is announcing 

an opportunity for the public to 

comment on the proposed collection of 

information listed above. Under the 

Paperwork Reduction Act of 1995 

(PRA), Federal agencies are required to 

publish a notice in the Federal Register 

concerning each proposed collection of 

information, including each proposed 

extension of an existing collection of 

information, and to allow 60 days for 

public comment in response to the 

notice. 

DATES: Comments on the collection of 

information must be submitted 

electronically by 11:59 p.m. (EST) or 

postmarked by February 5, 2024. 

ADDRESSES: Submit electronic 

comments on the collection of 

information to: Shannon Skowronski to 

the ACL Office of Performance and 

Evaluation public comment inbox at 

evaluation@acl.hhs.gov. Submit written 

comments on the collection of 

information to Administration for 

Community Living, 330 C Street SW, 

Washington, DC 20201, Attention: 

Shannon Skowronski Office of 

Performance and Evaluation. 

FOR FURTHER INFORMATION CONTACT: 

Shannon Skowronski at the ACL Office 

of Performance and Evaluation public 

comment inbox evaluation@acl.hhs.gov 

or at 202–795–7438 or 

shannon.skowronski@acl.hhs.gov. 

SUPPLEMENTARY INFORMATION: This 

announcement solicits comments on the 

ACL Program Performance Report 

Generic Information Collection, a 

mechanism to collect program 

performance reports for programs 

authorized by the Older Americans Act 

(Pub. L. 89–27 of 1965, as amended 

through Pub. L. 116–131 of 2020), and 

the Elder Justice Act (title XX of the 

Social Security Act, subtitle B, the Elder 

Justice Act of 2009). 

Under the PRA, Federal agencies must 

obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. ‘‘Collection of information’’ 

is defined as and includes agency 

requests or requirements that members 

of the public submit reports, keep 

records, or provide information to a 

third party. The PRA requires Federal 

agencies to provide a 60-day notice in 

the Federal Register concerning each 

proposed collection of information, 

including each proposed extension of an 

existing collection of information, 

before submitting the collection to OMB 

for approval. To comply with this 

requirement, ACL is publishing a notice 

of the proposed collection of 

information set forth in this document. 

ACL invites comments on burden 

estimates or other aspects of this 

collection of information, including: 

(1) whether the proposed collection of 

information is necessary for the proper 

performance of ACL’s functions, 

including whether the information will 

have practical utility; 

(2) the accuracy of ACL’s estimate of 

the burden of the proposed collection of 

information, including the validity of 

the methodology and assumptions used 

to determine burden estimates; 

(3) ways to enhance the quality, 

utility, and clarity of the information to 

be collected; and 

(4) ways to minimize the burden of 

the collection of information on 

respondents, including through the use 

of automated collection techniques 

when appropriate, and other forms of 

information technology. 

ACL will adhere to best practices for 

collection of all demographic 

information when this information is 

collected for the programs listed below 

in accordance with OMB guidance. This 

includes, but is not limited to, guidance 

specific to the collection of sexual 

orientation and gender identity (SOGI) 

items that align with Executive Order 

13985 on Advancing Racial Equity and 

Support for Underserved Communities 

Through the Federal Government, 

Executive Order 14075 on Advancing 

Equality for Lesbian, Gay, Bisexual, 

Transgender, Queer, and Intersex 

Individuals and Executive Order 13988 

on Preventing and Combating 

Discrimination on the Basis of Gender 

Identity and Sexual Orientation. 

Understanding these disparities can and 

should lead to improved service 

delivery for ACL’s programs and 

populations served. 

Authorizing Legislation 

In 1965, the Older Americans Act 

(OAA) was passed in response to 

concerns by policymakers about a lack 

of community social services for older 

adults. The original legislation 

established authority for grants for 

community planning and social 

services, research and development 

projects, and personnel training in the 

field of aging. The OAA was last 

amended in 2020 (Pub. L. 116–131) and 

authorizes a variety of social and health 

services programs for older adults, 

families, and caregivers. The Elder 

Justice Act (EJA), passed in 2010, is the 

first comprehensive legislation to 

address the abuse, neglect, and 

exploitation of older adults at the 

federal level. The law authorized 

programs and initiatives that coordinate 

federal responses to elder abuse, 

promote elder justice research and 

innovation, support Adult Protective 

Services systems, and provide 

additional protections for residents of 

long-term care facilities. OAA and EJA 

programs help advance ACL’s mission 

of supporting the independence, wellbeing, and health of older adults, older 

adults with disabilities, and their 

families and caregivers. 

The OAA, EJA, 45 CFR 75.342 

(monitoring and reporting program 

performance), 45 CFR 75.301 

(performance measurement), and the 

GPRA Modernization Act of 2010 (Pub. 

L. 111–352, Sec 12) require grantee 

program performance monitoring and 

reporting. Grantee program performance 

reporting serves several functions, 

enabling ACL to: (1) monitor program 

achievement of performance objectives; 

(2) identify areas of performance that 

may benefit from technical assistance 

and/or corrective action; (3) establish 

program policy and direction; and (4) 

prepare responses and reports for 

Congress, the OMB, other federal 

departments, and public and private 

agencies, including legislatively 

required reports. 

In order to streamline the collection of 

performance data and enhance efficacy, 

ACL is requesting approval of a generic 

IC for performance reporting for 

programs authorized under the OAA 

and EJA. 

The proposed data collection 

instruments may be found on the ACL 

website for review at: https:// 

www.acl.gov/about-acl/public-input. 

Estimated Program Burden: ACL 

estimated total annual burden for this 

generic IC is 50,335.60 hours. This 

estimate is based on the current number 

of grantees for these programs, their 

number of program performance 

indicators, and previous ACL 

experience with program performance 

reporting. 


khammond on DSKJM1Z7X2PROD with NOTICES
84336 Federal Register / Vol. 88, No. 232 / Tuesday, December 5, 2023 / Notices 

Respondent/data collection activity Number of 

respondents 

Responses 

per 

respondent 

Hours per 

response 

Annual burden 

hours 

State Formula Grantees, SPR Generic ........................................................... 112 1 70.3 7,873.60 

State Competitive Grants, PPR Generic ......................................................... 56 2 1.0 112 

Tribal Formula Grantees, PPR Generic .......................................................... 282 1 60 16,920 

Competitive Grantees, PPR Generic ............................................................... 1,189 2 10 23,780 

Veteran Organization Competitive Grantees, PPR Generic ........................... 275 12 0.5 1,650 

Total Annual Hours ................................................................................... ........................ ........................ ........................ 50,335.60 

Dated: November 30, 2023. 

Alison Barkoff, 

Principal Deputy Administrator for the 

Administration for Community Living, 

performing the delegable duties of the 

Administrator and the Assistant Secretary for 

Aging. 

[FR Doc. 2023–26634 Filed 12–4–23; 8:45 am] 

BILLING CODE 4154–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

Statement of Organization, Functions, 

and Delegations of Authority 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration’s (FDA), Center for 

Biologics Evaluation and Research 

(CBER), Office of Blood Research and 

Review (OBRR) and the Office of 

Vaccines Research and Review (OVRR) 

have modified organizational structures. 

DATES: These new organizational 

structures were approved by the 

Secretary of Health and Human Services 

on June 27, 2023. 

FOR FURTHER INFORMATION CONTACT: 

Yashika Rahaman, Director, Office of 

Planning, Evaluation and Risk 

Management, Office of Finance, Budget, 

Acquisitions and Planning, FDA, 4041 

Powder Mill Road, Beltsville, MD 

20705–4304, 301–796–3843. 

SUPPLEMENTARY INFORMATION: 

I. Introduction 

Part D, Chapter D–B, (Food and Drug 

Administration), the Statement of 

Organization, Functions and 

Delegations of Authority for the 

Department of Health and Human 

Services (35 FR 3685, February 25, 

1970, 60 FR 56606, November 9, 1995, 

64 FR 36361, July 6, 1999, 72 FR 50112, 

August 30, 2007, 74 FR 41713, August 

18, 2009, 76 FR 45270, July 28, 2011, 

and 84 FR 22854, May 20, 2019) is 

revised to reflect FDA’s reorganization 

of CBER, OBRR and OVRR. 

CBER’s mission is to protect and 

enhance public health through the 

regulation of biological and related 

products including blood, vaccines, 

allergenics, tissues, and cellular and 

gene therapies. With substantial growth 

in innovative, novel products, as well as 

a need to address an ever-changing 

landscape of potential public health 

threats, CBER is currently facing 

scientific, medical, and regulatory 

challenges that require changes to its 

structure. 

In OBRR, the establishment of a 

Laboratory of Pathogen Reduction will 

address Center-level initiatives focusing 

on the optimization of new pathogen 

inactivation technologies. These 

technologies can dramatically help the 

American public and potentially reduce 

or eliminate donor deferral and/or 

testing requirements. Additionally, the 

proposed structural changes, keeping 

OBRR’s functioning state of two 

divisions instead of three, will maintain 

operational consistency and enable the 

divisions to build on processes and 

efficiencies gained in the last 2 years. 

In OVRR, the Division of Vaccines 

and Related Product Applications will 

split into the Division of Review 

Management and Regulatory Review 

and the Division of Clinical and 

Toxicology Review to allow for 

improved operational efficiency, 

appropriate supervisory ratios, and a 

better balance of workload within an 

area of increased demand. 

Under Part D, FDA’s CBER, Office of 

Blood Research and Review, has been 

restructured as follows: 

DCB. ORGANIZATION. CBER is 

headed by the Center Director, Center 

for Biologics Evaluation and Research. 

Center for Biologics Evaluation and 

Research (DCB) 

Office of Blood Research and Review 

(DCBE) 

Administrative Staff (DCBE1) 

Regulatory Project Management Staff 

(DCBE2) 

Laboratory of Pathogen Reduction 

(DCBE3) 

Division of Emerging and Transfusion 

Transmitted Diseases (DCBEA) 

Laboratory of Molecular Virology 

(DCBEA1) 

Laboratory of Emerging Pathogens 

(DCBEA2) 

Product Review Branch (DCBEA4) 

Laboratory of Emerging Pathogens 

(DCBEA2) 

Product Review Branch (DCBEA4) 

Division of Blood Components and 

Devices (DCBEB) 

Devices Review Branch (DCBEB2) 

Blood and Plasma Branch (DCBEB6) 

Laboratory of Cellular Hematology 

(DCBEB7) 

Laboratory of Biochemistry and 

Vascular Biology (DCBEB8) 

Under Part D, FDA’s CBER, Office of 

Vaccines Research and Review, has 

been restructured as follows: 

DCB. ORGANIZATION. CBER is 

headed by the Center Director, Center 

for Biologics Evaluation and Research. 

Center for Biologics Evaluation and 

Research (DCB) 

Office of Vaccines Research and Review 

(DCBF) 

Program Operations Staff (DCBF1) 

Division of Bacterial Parasitic and 

Allergenic Products (DCBFA) 

Laboratory of ImmunoBiochemistry 

(DCBFA1) 

Laboratory of Respiratory and Special 

Pathogens (DCBFA2) 

Laboratory of Bacterial 

Polysaccharides (DCBFA3) 

Laboratory of Mucosal Pathogens and 

Cellular Immunology (DCBFA4) 

Division of Viral Products (DCBFB) 

Laboratory of Pediatric and 

Respiratory Viral Diseases 

(DCBFB1) 

Laboratory of Hepatitis Viruses 

(DCBFB2) 

Laboratory of Retroviruses (DCBFB3) 

Laboratory of DNA Viruses (DCBFB4) 

Laboratory of Vector Borne Diseases 

(DCBFB5) 

Laboratory of Method Development 

(DCBFB6) 

Laboratory of Immunoregulation 

(DCBFB7) 

Division of Review Management and 

Regulatory Review (DCBFD) 

Regulatory Review Branch 1 

(DCBFD1) 

Regulatory Review Branch 2 


khammond on DSKJM1Z7X2PROD with NOTICES